Literature DB >> 11052927

Plasma bradykinin levels in human chronic congestive heart failure.

M Cugno1, P Agostoni, H R Brunner, M Gardinali, A Agostoni, J Nussberger.   

Abstract

Induction of congestive heart failure by high-frequency pacing has been reported to increase plasma levels of immunoreactive kinins in dogs. In the present study, we evaluated plasma bradykinin levels in human heart failure. Utilizing a recently developed method, we specifically measured plasma levels of bradykinin-(1-9) nonapeptide in 21 patients with chronic congestive heart failure [New York Heart Association (NYHA) stages III and IV). At the same time, we measured plasma atrial natriuretic peptide levels and plasma renin activity, and, as a marker of inflammation, plasma levels of tumour necrosis factor. In addition, 18 healthy subjects matched for gender and age served as normal controls. Plasma bradykinin concentrations were not higher in patients with chronic congestive heart failure (median 2.1 fmol/ml) than in healthy subjects (2.6 fmol/ml). In contrast, plasma atrial natriuretic peptide levels were clearly higher (patients, 63 fmol/ml; controls, 24 fmol/ml; P<0.0001), despite diuretic treatment and in the presence of high plasma renin activity (patients, 13.0 ng x h(-1) x ml(-1); controls, 0.3 ng x h(-1) x ml(-1); P<0.0001). Tumour necrosis factor was elevated in heart failure patients in NYHA class IV only (27 pg/ml, compared with 21 pg/ml in controls; P=0.013). Bradykinin, atrial natriuretic peptide and plasma renin activity levels were not correlated with the severity of the disease, as assessed by NYHA classification. These results indicate that a rather selective cytokine activation, without concomitant stimulation of the kallikrein-kinin system, occurs in human chronic congestive heart failure.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11052927

Source DB:  PubMed          Journal:  Clin Sci (Lond)        ISSN: 0143-5221            Impact factor:   6.124


  6 in total

1.  Establishment of a Strategy for the Discovery and Verification of Low-Abundance Biomarker Peptides in Plasma Using Two Types of Stable-Isotope Tags.

Authors:  Yoshio Kodera; Yuya Hido; Rika Kato; Tatsuya Saito; Yusuke Kawashima; Satoru Minamida; Kazumasa Matsumoto; Masatsugu Iwamura
Journal:  Mass Spectrom (Tokyo)       Date:  2015-01-24

2.  Complement and contact system activation in acute congestive heart failure patients.

Authors:  C Suffritti; E Tobaldini; R Schiavon; S Strada; L Maggioni; S Mehta; G Sandrone; E Toschi-Dias; M Cicardi; N Montano
Journal:  Clin Exp Immunol       Date:  2017-08-04       Impact factor: 4.330

3.  A Single-Center, Open-Label, Randomized, Parallel-Group Study Assessing the Differences Between an Angiotensin II Receptor Antagonist and an Angiotensin-Converting Enzyme Inhibitor in Hypertensive Patients with Congestive Heart Failure: The Research for Efficacy of Angiotensin II Receptor Antagonist in Hypertensive Patients with Congestive Heart Failure Study.

Authors:  Nobuo Totsuka; Nobuhisa Awata; Katsuhito Takahashi; Hisako Yamamura; Junko Nakamura; Etsuo Tsuchikane; Yoshiki Kobayashi; Akira Nishibe; Kazuo Terai
Journal:  Curr Ther Res Clin Exp       Date:  2003-02

4.  Human Tissue Kallikrein Activity in Angiographically Documented Chronic Stable Coronary Artery Disease.

Authors:  Estêvão Lanna Figueiredo; Carolina Antunes Magalhães; Karlyse Claudino Belli; Ari Mandil; José Carlos Faria Garcia; Rosanã Aparecida Araújo; Amintas Fabiano de Souza Figueiredo; Lucia Campos Pellanda
Journal:  Arq Bras Cardiol       Date:  2015-09-04       Impact factor: 2.000

5.  In vitro inflammation inhibition model based on semi-continuous toll-like receptor biosensing.

Authors:  Jin-Woo Jeon; Un-Hwan Ha; Se-Hwan Paek
Journal:  PLoS One       Date:  2014-08-19       Impact factor: 3.240

6.  Comprehensive metabolic profiling of chronic low-grade inflammation among generally healthy individuals.

Authors:  Maik Pietzner; Anne Kaul; Ann-Kristin Henning; Gabi Kastenmüller; Anna Artati; Markus M Lerch; Jerzy Adamski; Matthias Nauck; Nele Friedrich
Journal:  BMC Med       Date:  2017-11-30       Impact factor: 8.775

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.